Phase II/III Study of AZD2816, for the Prevention of COVID-19 in Adults (AZD2816)
A Phase II/III Partially Double-Blinded, Randomised, Multinational, Active-Controlled Study in Both Previously Vaccinated and Unvaccinated Adults to Determine the Safety and Immunogenicity of AZD2816, a Vaccine for the Prevention of COVID-19 Caused by Variant Strains of SARS-CoV-2
Sponsor: AstraZeneca
A PHASE2/PHASE3 clinical study on COVID-19 and SARS-CoV-2, this trial is completed. The trial is conducted by AstraZeneca and has accumulated 13 data snapshots since 2021. Infectious disease trials contribute critical data for public health response and treatment development.
Status Flow
Change History
13 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2/PHASE3
-
Oct 2024 — Sep 2025 [monthly]
Completed PHASE2/PHASE3
-
Sep 2024 — Oct 2024 [monthly]
Completed PHASE2/PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2/PHASE3
Phase: PHASE2_PHASE3 → PHASE2/PHASE3
-
Feb 2023 — Jul 2024 [monthly]
Completed PHASE2_PHASE3
▶ Show 8 earlier versions
-
Sep 2022 — Feb 2023 [monthly]
Completed PHASE2_PHASE3
Status: Active Not Recruiting → Completed
-
Jul 2022 — Sep 2022 [monthly]
Active Not Recruiting PHASE2_PHASE3
-
Apr 2022 — Jul 2022 [monthly]
Active Not Recruiting PHASE2_PHASE3
-
Feb 2022 — Apr 2022 [monthly]
Active Not Recruiting PHASE2_PHASE3
-
Jan 2022 — Feb 2022 [monthly]
Active Not Recruiting PHASE2_PHASE3
Status: Recruiting → Active Not Recruiting
-
Dec 2021 — Jan 2022 [monthly]
Recruiting PHASE2_PHASE3
-
Oct 2021 — Dec 2021 [monthly]
Recruiting PHASE2_PHASE3
-
Sep 2021 — Oct 2021 [monthly]
Recruiting PHASE2_PHASE3
First recorded
Jun 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- AstraZeneca
For direct contact, visit the study record on ClinicalTrials.gov .